Literature DB >> 19263010

[Contrast induced nephropathy].

Walter H Hörl1.   

Abstract

Contrast media induced nephropathy is a common complication, particularly in high risk patients, such as patients with chronic kidney disease (CKD) and diabetes. The majority of studies show an increased in-hospital mortality and an unfavourable long-term prognosis after manifestation of contrast media induced nephropathy. The course and the potential risk factors of this type of acute renal failure are known. Therefore, an effective prophylaxis should allow to prevent this complication. In low risk patients oral or intravenous volume expansion is probably sufficient combined with the withdrawal of non-steroidal anti-inflammatory drugs. In high risk patients additional prophylactic measures are needed but their efficacy is not clearly defined. Therefore, heterogeneous recommendations exist. Hydration reduces (afferent) renovasoconstriction, the tubuloglomerular feedback, the tubulotoxic effects of contrast media (via dilution) and the oxygen radical formation. The optimal composition, timing and amount of fluid which should be administered to the patients remain unclear. Most studies show that intravenous administration of volume is more effective than oral fluid intake. The majority of studies found a benefit of isotonic sodium bicarbonate in comparison to isotonic saline solutions, even if meta-analyses displayed only a positive trend for sodium bicarbionate due to the heterogeneity of the data. Controversies exist for N-acetylcysteine, vitamin C, fenoldopam, theophylline or statins. Due to low cost and low side effects, N-Acetylcysteine is widely used. Theophyllin (given intravenously 30 minutes before contrast media injection) is renoprotective, particularly in intensive care unit patients. Very important is the reduction of contrast media volume (if possible <30 ml for diagnostic procedures and <100 ml for interventions). Iso-osmolar and low-osmolar contrast media may have a comparable low risk for the induction of contrast media induced nephropathy. This risk is probably higher after intra-arterial as compared to intravenous administration of contrast media. Controversies exist with respect to the reduction of contrast media induced nephropathy and mortality by prophylactic hemodialysis or hemofiltration. A possible benefit of these procedures consists probably for patients with advanced chronic kidney disease (stage 5). With the further increase of investigations using contrast media, with the further increase in vascular interventions, in age and comorbidities of the patients one may suggest that the problem of contrast media induced nephropathy will further increase, despite all prophylactic procedures so far recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19263010     DOI: 10.1007/s00508-009-1145-3

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  125 in total

1.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.

Authors:  George Dangas; Ioannis Iakovou; Eugenia Nikolsky; Eve D Aymong; Gary S Mintz; Nicholas N Kipshidze; Alexandra J Lansky; Issam Moussa; Gregg W Stone; Jeffrey W Moses; Martin B Leon; Roxana Mehran
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

2.  Contrast nephropathy in patients with impaired renal function: high versus low osmolar media.

Authors:  B J Barrett; P S Parfrey; H M Vavasour; J McDonald; G Kent; D Hefferton; F O'Dea; E Stone; R Reddy; P J McManamon
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

3.  The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.

Authors:  L Gruberg; G S Mintz; R Mehran; G Gangas; A J Lansky; K M Kent; A D Pichard; L F Satler; M B Leon
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

4.  Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.

Authors:  P Liss; P B Persson; P Hansell; B Lagerqvist
Journal:  Kidney Int       Date:  2006-09-27       Impact factor: 10.612

Review 5.  Dialysis and iodinated contrast media.

Authors:  G Deray
Journal:  Kidney Int Suppl       Date:  2006-04       Impact factor: 10.545

6.  Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis.

Authors:  Joachim H Ix; Charles E McCulloch; Glenn M Chertow
Journal:  Nephrol Dial Transplant       Date:  2004-08-24       Impact factor: 5.992

7.  Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial.

Authors:  Birgit Hölscher; Christine Heitmeyer; Manfred Fobker; Günter Breithardt; Roland M Schaefer; Holger Reinecke
Journal:  Can J Cardiol       Date:  2008-11       Impact factor: 5.223

8.  Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases.

Authors:  E C Keeley; C L Grines
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

9.  The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.

Authors:  Alejandro Recio-Mayoral; Marinela Chaparro; Belén Prado; Rocío Cózar; Irene Méndez; Debasish Banerjee; Juan C Kaski; José Cubero; Jose M Cruz
Journal:  J Am Coll Cardiol       Date:  2007-03-12       Impact factor: 24.094

Review 10.  Prevention of contrast-induced nephropathy: a critical review.

Authors:  Jens T Van Praet; An S De Vriese
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-07       Impact factor: 2.894

View more
  2 in total

1.  Radiocontrast-induced acute kidney injury in the ICU: worse than presumed?

Authors:  Michael Joannidis; Christian J Wiedermann
Journal:  Intensive Care Med       Date:  2011-11-03       Impact factor: 17.440

Review 2.  ACE-I/ARB therapy prior to contrast exposure: what should the clinician do?

Authors:  Robert Kalyesubula; Peace Bagasha; Mark A Perazella
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.